phase evalu safeti immunogen vaccin recombin patient earli human immunodefici viru infect militari medic consortium appli retrovir research background multipl antivir humor cellular immun respons infect human immunodefici viru hiv result debilit diseas effect immun respons post-infect vaccin hiv-specif antigen method phase trial safeti immunogen vaccin envelop protein volunt subject hiv infect walter reed stage vaccin day day hiv-specif humor cellular immun respons local system reaction vaccin gener measur immun function result subject humor cellular immun hiv envelop protein respons vaccin seroconvers envelop epitop new t-cell prolif respons respons cell count vaccin subject percent cell millilit percent equal cell millilit number inject percent subject inject percent inject local reaction site inject mild advers system reaction diminut gener vitro vivo cellular immun function month follow-up mean count subject percent conclus vaccin safe immunogen volunt patient earli hiv infect earli approach use scientif therapeut evalu hiv-specif vaccin therapi similar vaccin effect chronic infect 